Compare stocks

GRCE vs SUPN

Grace Therapeutics, Inc. Common Stock and Supernus, Inc. Common Stock

Compare the businesses

Grace Therapeutics, Inc. Common Stock

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Open GRCE dashboard ↗

Supernus, Inc. Common Stock

Supernus Inc is a diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases. The company's commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea.

Open SUPN dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗